ARTICLE | Company News
Novartis sales and marketing update
May 4, 2009 7:00 AM UTC
Genentech Inc. and Novartis co-market Xolair, a recombinant humanized mAb against IgE, in the U.S., and Novartis markets it elsewhere. Lucentis, a humanized mAb fragment against VEGF-A, is marketed ...